Zielinski, R. R. (2014) “Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer”, Canadian Urological Association Journal, 8(7-8), pp. e520–3. doi: 10.5489/cuaj.2076.